Victoria Covel - Sonoma Pharmaceuticals Assistant Controller
| SNOA Stock | USD 2.81 0.02 0.72% |
Insider
Victoria Covel is Assistant Controller of Sonoma Pharmaceuticals
| Address | 5445 Conestoga Court, Boulder, CO, United States, 80301 |
| Phone | 800 759 9305 |
| Web | https://sonomapharma.com |
Sonoma Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1959) % which means that it has lost $0.1959 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7465) %, meaning that it created substantial loss on money invested by shareholders. Sonoma Pharmaceuticals' management efficiency ratios could be used to measure how well Sonoma Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of December 3, 2024, Return On Tangible Assets is expected to decline to -0.34. In addition to that, Return On Capital Employed is expected to decline to -0.45. At present, Sonoma Pharmaceuticals' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 12.6 M, whereas Return On Tangible Assets are forecasted to decline to (0.34).Similar Executives
| Showing other executives | INSIDER Age | ||
| David MD | Passage Bio | N/A | |
| Adriana MBA | Crinetics Pharmaceuticals | N/A | |
| Path FRCP | Revolution Medicines | 61 | |
| BA BA | Oric Pharmaceuticals | 63 | |
| Malinda Longphre | Connect Biopharma Holdings | N/A | |
| Richard Heyman | Oric Pharmaceuticals | 67 | |
| Simon Latimer | Ligand Pharmaceuticals Incorpor | N/A | |
| Lori Friedman | Oric Pharmaceuticals | 60 | |
| MPH MD | Connect Biopharma Holdings | 54 | |
| Audrey WarfieldGraham | Ligand Pharmaceuticals Incorpor | N/A | |
| Aseem Ansari | Design Therapeutics | N/A | |
| Raul Collazo | Connect Biopharma Holdings | N/A | |
| Steven Chan | Connect Biopharma Holdings | 52 | |
| David Pompliano | Revolution Medicines | N/A | |
| Gary Lee | Lyell Immunopharma | 47 | |
| Jeff Knight | Crinetics Pharmaceuticals | 53 | |
| Scott Lowe | Oric Pharmaceuticals | N/A | |
| Lei Sun | Connect Biopharma Holdings | 60 | |
| David Clark | Amicus Therapeutics | 48 | |
| Walter Reiher | Revolution Medicines | N/A | |
| Michael Fischbach | Revolution Medicines | 43 | |
Management Performance
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.2 |
Sonoma Pharmaceuticals Leadership Team
Elected by the shareholders, the Sonoma Pharmaceuticals' board of directors comprises two types of representatives: Sonoma Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sonoma. The board's role is to monitor Sonoma Pharmaceuticals' management team and ensure that shareholders' interests are well served. Sonoma Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sonoma Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Northey, Executive Vice President - Research and Development | ||
| Jerome Dvonch, Interim Officer | ||
| John Poggetto, Controller | ||
| Amy Trombly, President CEO | ||
| Bruce Thornton, Executive Vice President - International Operations and Sales | ||
| Victoria Covel, Assistant Controller | ||
| Chad White, Interim Officer |
Sonoma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sonoma Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.75 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (0.36) % | ||||
| Operating Margin | (0.35) % | ||||
| Current Valuation | (97.72 K) | ||||
| Shares Outstanding | 1.34 M | ||||
| Shares Owned By Insiders | 1.50 % | ||||
| Shares Owned By Institutions | 2.41 % | ||||
| Number Of Shares Shorted | 77.03 K | ||||
| Price To Earning | 2.57 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sonoma Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonoma Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonoma Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonoma Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonoma Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonoma Pharmaceuticals. If investors know Sonoma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonoma Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.99) | Revenue Per Share 20.967 | Quarterly Revenue Growth (0.01) | Return On Assets (0.20) | Return On Equity (0.75) |
The market value of Sonoma Pharmaceuticals is measured differently than its book value, which is the value of Sonoma that is recorded on the company's balance sheet. Investors also form their own opinion of Sonoma Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Sonoma Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonoma Pharmaceuticals' market value can be influenced by many factors that don't directly affect Sonoma Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonoma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonoma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonoma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.